Literature DB >> 11772311

Therapeutic potential of mycobacterial cell wall-DNA complexes.

M C Filion1, N C Phillips.   

Abstract

Cell wall skeletons isolated from many bacteria have been shown to possess anticancer activity. The anticancer activities of such preparations have been attributed to the activation of immune effector cells and not to a direct effect on cancer cell division. A cell wall extract from Mycobacterium phlei, wherein mycobacterial DNA in the form of short oligonulceotides is preserved to the cell wall, has anticancer activity against a wide range of cancer cells. Mycobacterial cell wall-DNA complexes (MCC) exert their anticancer activity by a dual mechanism of action: an indirect effect via the induction of anticancer cytokines and a direct effect on cancer cell division mediated by the induction of apoptosis. In this review, the immunomodulatory and the pro-apoptotic mechanisms of action of MCC will be explored. The identification of the active component in MCC will be discussed, as well as the composition differences with cell wall skeletons and live mycobacteria. Finally, the use of MCC against bladder and prostate cancers will be discussed and compared to standard therapies, particularly therapy using mycobacteria and mycobacteria-derived products.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11772311     DOI: 10.1517/13543784.10.12.2157

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  8 in total

1.  Administration of Mycobacterium phlei cell wall-nucleic acid complex in the immediate postoperative period for the treatment of non-muscle-invasive bladder cancer.

Authors:  Álvaro Morales
Journal:  Can Urol Assoc J       Date:  2016 Sep-Oct       Impact factor: 1.862

2.  Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).

Authors:  Michael D Weintraub; Qingdi Quentin Li; Piyush K Agarwal
Journal:  Mol Clin Oncol       Date:  2014-06-12

Review 3.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

Review 4.  The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer.

Authors:  Vignesh T Packiam; Shane M Pearce; Gary D Steinberg
Journal:  Ther Adv Urol       Date:  2016-02

Review 5.  Toll-like receptors in urothelial cells--targets for cancer immunotherapy.

Authors:  Hélène LaRue; Cherifa Ayari; Alain Bergeron; Yves Fradet
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

6.  Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients.

Authors:  Roger Li; John Amrhein; Zvi Cohen; Monique Champagne; Ashish M Kamat
Journal:  Bladder Cancer       Date:  2017-01-27

7.  The Mycobacterium phlei Genome: Expectations and Surprises.

Authors:  Sarbashis Das; B M Fredrik Pettersson; Phani Rama Krishna Behra; Malavika Ramesh; Santanu Dasgupta; Alok Bhattacharya; Leif A Kirsebom
Journal:  Genome Biol Evol       Date:  2016-04-08       Impact factor: 3.416

Review 8.  Intravesical immunotherapy in nonmuscle invasive bladder cancer.

Authors:  Jan-Friedrich Jokisch; Alexander Karl; Christian Stief
Journal:  Indian J Urol       Date:  2015 Oct-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.